Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Is March back?

Fri, 30th Oct 2020 11:00

* STOXX on track for worst month since March

* Miners down after Glencore results

* Oil and gas stock index leads gains

* Ubisoft shares slump as the game maker cuts its FY
guidance
Welcome to the home for real-time coverage of markets brought to
you by Reuters reporters. You can share your thoughts with us at
markets.research@thomsonreuters.com

IS MARCH BACK? (1100 GMT)

Growing cases of COVID-19 and new national lockdowns in two
of Europe's largest economies put European shares on track for
its worst month since March's brutal selloff, and it is getting
clear to investors that it is the case to price in more pain.

"Even a successful vaccine is unlikely to become widely
available before Q2 2021, more economic pain looks inevitable,"
writes Barclays.

But how much pain shall we price in?

Barclays analysts think things won't get as bad for the
economy as it did in the spring "with many businesses and,
importantly, schools remaining open. Government support programs
are being extended and targeted more precisely, which should
provide much needed cushion to activity".

"Although the slow progress on the EU recovery fund is
problematic", Barclays expects the ECB to boost its policy
support in December with a 6-month Eur500bn extension for its
Pandemic Emergency Purchase Programme, an increased monthly
Asset Purchase Programme and further easing of the TLTRO
(targeted longer-term refinancing operations) terms.

Additionally, it says the resurgence seems "less global" as
it hasn't hit China and Asia but mostly Europe and the U.S.

Barclays hasn't made much change to its equity strategy in
October because last month, it had already reduced cyclical
exposure on rising concerns about a second wave.

It downgraded consumer discretionary to underweight, as the
sector is highly exposed to mobility and social restrictions;
and upgraded staples to market weight, as a defensive hedge.

"We acknowledge that a concerted slowing in activity
may warrant further targeted action to reduce cyclical exposure.
But for now, we remain comfortable being overweight
China/stimulus/North Asia/tech exposed cyclicals like miners,
industrials and tech," Barclays strategists say.

(Joice Alves)

*****

BANKS UP, TECH AND BASIC MATERIALS DOWN (0855 GMT)

European equities are in negative territory but the fall is
less severe than anticipated by futures as strong company
results are supporting the pan-European index, which
though is still set to stage its worst month since March.

The STOXX 600 index is dropping 0.3% with tech stocks among
the worst performers, following mixed results from U.S. tech
giants and a fall in Apple on Wall Street.

The Spanish banking index is up 1.2% as shares in
Banco de Sabadell, Caixabank < CABK.MC > and BBVA
are flat to higher after results.

Europe's basic materials index is down 0.6%, after
Glencore posted stronger production but trimmed coal
production guidance as a strike at the Cerrejon mine in Colombia
entered its 60th day on Friday. Glencore stocks fell 1.5%.

Shares in Proximus are among the winners of the
session up 7.7% after the company reported Ebitda above analysts
expectations and raised its full year guidance.

(Stefano Rebaudo)

*****

ON THE RADAR: TOTAL, SWISS RE, SPANISH BANKS (0738 GMT)

European stocks are set to open sharply lower as worries
about possible new lockdowns coupled with risks of a contested
outcome of U.S. elections rattle investors.

A batch of positive results is not giving much support.

Swiss Re stocks are up 0.5% in premarket trade as
the reinsurance company reported a smaller-than-expected net
loss in the first nine months after booking claims and reserves
of $3 billion related to COVID-19.

Total trimmed its investment target for 2020,
though the group returned to profit in the third quarter and
maintained its dividend.

The pandemic hit results of Spanish banks, which however
came out better than expected.

Banco Sabadell's third-quarter net profit fell 77%
from a year ago due to higher provisions but beat forecast,
while the lender announced an efficiency plan.

Caixabank posted a net profit of 522 million euros
versus analysts’ expectations of 319 million euros.

BBVA net profit beat market expectations, but was
down 6.9% from the same period a year ago to 1.14 billion euros
on more loan loss provisions.

Air France-KLM unveiled a 1.05 billion-euro better
than expected operating loss and warned of worse to come as a
resurgent coronavirus brings new travel curbs.

Shares in LafargeHolcim are up 0.7% after the
company raised its guidance, after results.

Proximus reported Ebitda above analysts
expectations and raised its full year guidance.

Amundi reported a high level of net inflows and
an operating income of 307 million euros.

BP plans to stop producing fuel in Australia and will
convert its loss-making Kwinana oil refinery, the biggest of the
country's four.

Julius Baer Gruppe plans to set up business in
China in partnership with a local financial firm.

Lonza Group agreed with AstraZeneca to make
AZD7442 an experimental combination of two antibodies that may
be used to prevent and treat COVID-19.

(Stefano Rebaudo)

*****

EUROPE'S STOCK FUTURES WELL IN THE RED (0628 GMT)

European stock futures are sharply lower as record numbers
of coronavirus cases across the world and the outcome of U.S.
elections remain the major concern for investors.

The ECB signalling it will provide more stimulus to fight
the impact of the pandemic gave some support to stocks yesterday
but wasn’t far from analysts’ expectations.

U.S. stock futures are down around 2%, after a positive
session on Wall Street, helped by quarterly reports from tech
giants and solid GDP data.

(Stefano Rebaudo)

*****

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.